What question did this study set out to answer?

To explore a platform for manufacturing and validating in vivo-expressed biologics for immunotherapy applications.

In Vivo-Expressed Biologics: A New Paradigm for Immunotherapy Manufacturing

View Full Paper

Ask AI

Bookmark

Authors

This abstract examines in vivo biologics for immunotherapy, showing efficient production and functionality in targeted treatments.

To explore a platform for manufacturing and validating in vivo-expressed biologics for immunotherapy applications.
Developed an mRNA-LNP platform for therapeutic antibody and CAR T cell expression.
Demonstrated efficiency of mRNA-encoded trastuzumab in various models.
Utilized lipid nanoparticles for non-viral delivery of HER2-CAR mRNA.
Conducted functional cytotoxicity assays to evaluate CAR T cell efficacy.
mRNA-encoded trastuzumab showed similar specificity and potency to recombinant antibodies.
In vivo studies indicated superior tumor growth control with lower doses than protein infusions.
>65% CAR-positive T cells were generated from primary human T cells.
Robust cytotoxic responses were confirmed against HER2-expressing targets.

Leonard et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark